Are Cannabis Stocks a Good Investment?

Cannabis stocks present a compelling but complex investment thesis. The global legal cannabis market is projected to exceed $60 billion by 2028, driven by expanding legalization, growing consumer acceptance, and the emergence of new product categories. For investors with higher risk tolerance, the sector offers exposure to one of the fastest-growing industries in North America.

However, cannabis stocks have historically been among the most volatile equities on the market. The MSOS ETF, which tracks US multi-state operators, has experienced drawdowns exceeding 80% from its 2021 highs. Many cannabis companies continue to burn cash, dilute shareholders, and struggle with profitability under the weight of Section 280E tax burdens that prevent them from deducting ordinary business expenses.

The investment case largely hinges on regulatory catalysts. Federal rescheduling from Schedule I to Schedule III would eliminate the 280E tax burden, potentially doubling or tripling cash flows for profitable operators overnight. Full legalization or the passage of the SAFE Banking Act would further unlock institutional capital, major exchange listings, and traditional banking relationships that the sector currently lacks.

For investors considering cannabis stocks, diversification is critical. The sector includes multi-state operators (MSOs) like Curaleaf and Green Thumb Industries, Canadian licensed producers (LPs) like Tilray and Canopy Growth, ancillary companies that serve the industry without touching the plant, and cannabis-focused ETFs that spread risk across multiple holdings. Each segment carries different risk and reward profiles.

The bottom line is that cannabis stocks can be a good investment for those who understand the risks, have a long time horizon, and can tolerate extreme volatility. Position sizing should reflect the speculative nature of the sector — most financial advisors suggest limiting cannabis exposure to a small percentage of an overall portfolio.